A lot of studies are focused on the optimization of CD38-targeting antibodies in multiple myeloma, as well as the elucidation of the detailed mechanism of action from the point of patient exposure to the development of a refractory response, and rightly so. This evidence concerns the gene CD38 and AL amyloidosis.